TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered with Avantor Inc., a provider of mission-critical products and services to customers in the life sciences and advanced technology industries, to expand the availability of its nucleic acid products to customers across Europe, Middle East, and Africa (EMEA).
This distribution partnership is expected to improve the ordering process and offer shorter lead times for European customers—increasing access to TriLink’s novel nucleic acid technologies.
Through the agreement, TriLink’s products will now be more widely available in EMEA, including its CleanCap cap analogs (co-transcriptional mRNA caps), catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes like CleanScribe RNA Polymerase – all of which can be adapted for research use only (RUO) or manufactured at GMP-grade. Additionally, TriLink products will be available through VWR’s eCommerce platform, MarketSource, in the coming months.
“This partnership marks an important step in expanding access to our cutting-edge nucleic acid technologies across Europe,” said Becky Buzzeo, Chief Commercial Officer at TriLink. “By collaborating with a trusted partner like Avantor and leveraging their unmatched distribution network, we can better serve the region’s growing demand for innovative solutions and support the advancement of life-changing therapeutic research.”
Related news: Avantor Opens Flagship Bridgewater Innovation Center
